Biodrugs

Biodrugs

生物药物

  • 2区 中科院分区
  • Q1 JCR分区

期刊简介

《Biodrugs》是由Springer International Publishing出版社于1994年创办的英文国际期刊(ISSN: 1173-8804,E-ISSN: 1179-190X),该期刊长期致力于药学领域的创新研究,主要研究方向为免疫学-医学。作为SCIE收录期刊(JCR分区 Q1,中科院 2区),本刊采用OA未开放获取模式(OA占比0.4882...%),以发表药学领域等方向的原创性研究为核心(研究类文章占比46.77%%)。凭借严格的同行评审与高效编辑流程,期刊年载文量精选控制在62篇,确保学术质量与前沿性。成果覆盖Web of Science、Scopus等国际权威数据库,为学者提供推动医学领域高水平交流平台。

投稿咨询

投稿提示

Biodrugs审稿周期约为 12周,或约稿 。该刊近年未被列入国际预警名单,年发文量约62篇,录用竞争适中,主题需确保紧密契合医学前沿。投稿策略提示:避开学术会议旺季投稿以缩短周期,语言建议专业润色提升可读性。

  • 医学 大类学科
  • English 出版语言
  • 是否预警
  • SCIE 期刊收录
  • 62 发文量

中科院分区

中科院 SCI 期刊分区 2023年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
2区
PHARMACOLOGY & PHARMACY 药学 IMMUNOLOGY 免疫学 ONCOLOGY 肿瘤学
1区 2区 2区

中科院 SCI 期刊分区 2022年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
2区
PHARMACOLOGY & PHARMACY 药学 IMMUNOLOGY 免疫学 ONCOLOGY 肿瘤学
1区 2区 2区

JCR分区

按JIF指标学科分区 收录子集 分区 排名 百分位
学科:IMMUNOLOGY SCIE Q1 42 / 181

77.1%

学科:ONCOLOGY SCIE Q1 60 / 322

81.5%

学科:PHARMACOLOGY & PHARMACY SCIE Q1 32 / 354

91.1%

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:IMMUNOLOGY SCIE Q1 37 / 181

79.83%

学科:ONCOLOGY SCIE Q1 72 / 322

77.8%

学科:PHARMACOLOGY & PHARMACY SCIE Q1 73 / 354

79.52%

CiteScore

CiteScore SJR SNIP CiteScore 排名
CiteScore:12.6 SJR:1.796 SNIP:1.506
学科类别 分区 排名 百分位
大类:Medicine 小类:Pharmacology (medical) Q1 10 / 272

96%

大类:Medicine 小类:Pharmacology Q1 24 / 313

92%

大类:Medicine 小类:Biotechnology Q1 29 / 311

90%

期刊发文

  • Comparison of Pharmacokinetic Similarity, Immunogenicity, and Safety of Ustekinumab and BAT2206 in Healthy Chinese Male Subjects in a Double-Blind, Randomized, Single-Dose, Parallel-Group Phase I Trial

    Author: Wu, Min; Li, Xiaojiao; Yang, Deming; Wang, Meng; Zhang, Hong; Li, Cuiyun; Mai, Jiajia; Yang, Lizhi; Qi, Yunpeng; Yu, Jin-Chen; Yang, Xiaolei; Wang, Zhaohe; Gu, Cailing; Ding, Yanhua

    Journal: BIODRUGS. 2023; Vol. 37, Issue 1, pp. 89-98. DOI: 10.1007/s40259-022-00563-5

  • Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities

    Author: Jiang, Yuxiong; Chen, Youdong; Yu, Qian; Shi, Yuling

    Journal: BIODRUGS. 2023; Vol. 37, Issue 1, pp. 35-55. DOI: 10.1007/s40259-022-00569-z

  • Current Progress and Challenges in the Study of Adjuvants for Oral Vaccines

    Author: Ou, Bingming; Yang, Ying; Lv, Haihui; Lin, Xin; Zhang, Minyu

    Journal: BIODRUGS. 2023; Vol. 37, Issue 2, pp. 143-180. DOI: 10.1007/s40259-022-00575-1

  • Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial

    Author: Li, Huiping; Huang, Yan; Chen, Zhendong; Zeng, Aiping; Zhang, Helong; Yu, Yan; Wei, Shihong; Li, Qingshan; Wang, Xiaojia; Wang, Xiangcai; Wang, Xiuwen; Yang, Runxiang; Dai, Xiumei; Bi, Minghong; Sun, Tao; Zhang, Qingyuan; Han, Cuicui; Li, Yujie; Kang, Xiaoyan; Liu, Yaxin; Zhang, Li

    Journal: BIODRUGS. 2023; Vol. 37, Issue 2, pp. 259-269. DOI: 10.1007/s40259-023-00579-5

  • Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing

    Author: Shao, Taihang; Zhao, Mingye; Liang, Leyi; Tang, Wenxi

    Journal: BIODRUGS. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s40259-023-00586-6

  • Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis

    Author: Peng, Kuan; Blais, Joseph E.; Pratt, Nicole L.; Guo, Jeff Jianfei; Hillen, Jodie B.; Stanford, Tyman; Ward, Michael; Lai, Edward Chia-Cheng; Shin, Ju-Young; Tong, Xinning; Fan, Min; Cheng, Franco W. T.; Wu, Jing; Yeung, Winnie W. Y.; Lau, Chak-Sing; Leung, Wai Keung; Wong, Ian C. K.; Li, Xue

    Journal: BIODRUGS. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s40259-023-00589-3

  • Advanced Delivery Strategies for Immunotherapy in Type I Diabetes Mellitus

    Author: Huang, Mingshu; Chen, Weixing; Wang, Min; Huang, Yisheng; Liu, Hongyu; Ming, Yue; Chen, Yuanxin; Tang, Zhengming; Jia, Bo

    Journal: BIODRUGS. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s40259-023-00594-6

  • A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of Proposed Biosimilar GB242 and Reference Infliximab in Healthy Subjects

    Author: Tan Zhang, Guihong Chen, Chang Liu, Li’an Zu, Qi Wang, Yitong Wang, Jie Lv, Youzhong An, Lihou Dong, Huiyang Cheng, Shengbin Ren, Qian Wang, Qingshan Zheng, Haifeng Song, Yi Fang

    Journal: BIODRUGS, 2018, Vol., , DOI:10.1007/s40259-018-0326-x